Results 191 to 200 of about 2,311,261 (354)

Targeting ferroptosis to overcome drug resistance in lung cancer. [PDF]

open access: yesTransl Lung Cancer Res
Sheng P   +7 more
europepmc   +1 more source

Drug-resistant tuberculosis

open access: yesThe Lancet, 1993
B A, Hanna, S, Bonk, L K, Tick
openaire   +2 more sources

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Identification of Specific LncRNA Markers in Severe Tuberculosis for Early Diagnosis

open access: yesInfection and Drug Resistance
Siyu Yao,1,* Xiuxiu Ji,2,* Ruize Wang,1 Liping Pan,2 Qiuyue Liu1 1Department of Critical Care Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, People’s ...
Yao S, Ji X, Wang R, Pan L, Liu Q
doaj  

Outsmarting Nightmare: Drug Resistance in <i>Acinetobacter baumannii</i>. [PDF]

open access: yesCan J Infect Dis Med Microbiol
Praveen A   +4 more
europepmc   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy